2016 - 2018年浦东新区流感疫苗疑似预防接种异常反应监测结果分析

目的 评价浦东新区2016 - 2018年流感疫苗预防接种的安全性，为流感疫苗接种提供科学依据。方法 收集疑似预防接种异常反应信息管理系统中2016 - 2018年浦东新区流感疫苗疑似预防接种异常反应（adverse events following immunization，AEFI）监测数据，采用R3.4软件进行统计分析。结果 2016 - 2018年浦东新区流感疫苗AEFI报告发生率为15.72/100万剂次，其中一般反应报告发生率为15.68/100万剂次，异常反应报告发生率为0.05/100万剂次，未发现偶合症和心因性反应。2016 - 2018年接种疫苗发热者288例，占82.76%；局部红肿64例，占18.39%，局部硬结14例，占4.02%，其他症状间73例，占20.98%。接种0.25 ml剂量发热者199例(69.10%)，接种0.50 ml剂量发热者89例(30.90%)，不同接种剂量发热率差异有统计学意义（P = 0.040）。结论 浦东新区流感疫苗AEFI报告发生率低于其他省份，应继续强化接种门诊人员培训，积极开展预防接种宣传，加强流感疫苗AEFI监测，提升疫苗AEFI数据的可信性。

Analysis of adverse events following immunization of influenza vaccine in Pudong new area from 2016 to 2018

Objective To evaluate the safety of influenza vaccine in Pudong New Area from 2016 to 2018 and provide scientific basis for influenza vaccination. Methods We collected the data of adverse events following immunization (AEFI) of influenza vaccine in Pudong New Area in 2016-2018 from adverse events following immunization information management system, and R3.4 software was used for statistical analysis. Results The incidence of AEFI report of influenza vaccine in Pudong New Area in 2016-2018 was 15.72 per million doses, of which the general reaction report rate was 15.68 per million doses, and the abnormal reaction report rate was 0.05 per million doses. No coupling symptoms and psychogenic reactions were found. There were 288 cases of vaccination fever which accounted for 82.76% from 2016 to 2018; the number of local redness was 64 cases which accounted for 18.39%; the number of local induration symptoms was 14 cases which accounted for 4.02%, and the number of other symptoms was 73 cases which accounted for 20.98%. Inoculation of 0.25 ml of abnormal body temperature 199(69.10%), inoculation of 0.50 ml dose of abnormal body temperature 89(30.90%), the difference in body temperature abnormal rate of different inoculation doses was statistically significant(P=0.040). Conclusion The incidence of influenza vaccine AEFI in Pudong New Area is lower than other provinces, and the training of vaccination clinic staff and vaccination propaganda should be actively carried out. Continuous surveillance on influenza vaccine of AEFI should be strengthened to enhance the credibility of AEFI data.